Pharmaceutical groups Boehringer Ingelheim and Shire as well as Japanese conglomerate Mitsui’s corporate venturing unit and ATMI have helped Université Catholique de Louvain’s liver treatment spin out Promethera Biosciences raise €17m ($22.7m). The companies were joined in the series B round for the Belgium-based cell therapy company, on Wednesday, by Belgium-based venture capital firm SambrInvest.…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
